Passage Bio (PASG) Projected to Post Quarterly Earnings on Wednesday

Passage Bio (NASDAQ:PASG) is projected to post its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Passage Bio to post earnings of ($2.64) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 19, 2025 at 7:00 AM ET.

Passage Bio (NASDAQ:PASG) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($2.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $1.04. On average, analysts expect Passage Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Passage Bio Price Performance

PASG opened at $6.28 on Monday. The company has a market capitalization of $19.97 million, a P/E ratio of -0.35 and a beta of 1.94. The firm’s fifty day moving average price is $7.59 and its two-hundred day moving average price is $7.28. Passage Bio has a fifty-two week low of $5.12 and a fifty-two week high of $26.60.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wedbush upped their price objective on Passage Bio to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. Canaccord Genuity Group dropped their target price on Passage Bio from $260.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Wall Street Zen raised Passage Bio to a “hold” rating in a research note on Friday, September 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Passage Bio in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Passage Bio has an average rating of “Moderate Buy” and a consensus target price of $75.67.

Insiders Place Their Bets

In other Passage Bio news, major shareholder Lynx1 Capital Management Lp purchased 19,783 shares of the stock in a transaction on Friday, September 12th. The shares were purchased at an average price of $6.99 per share, with a total value of $138,283.17. Following the completion of the transaction, the insider directly owned 611,804 shares in the company, valued at $4,276,509.96. This represents a 3.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired 32,008 shares of company stock worth $223,726 in the last 90 days. 4.30% of the stock is currently owned by insiders.

Passage Bio Company Profile

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.